Vertex Pharmaceuticals
4 articles
Industry NewsSummit Therapeutics / Capricor / Vertex PharmaceuticalsBioSpace
FDA's Crowded November: Ivonescimab, Deramiocel and Povetacicept Face Verdicts
- Summit's ivonescimab for EGFR-mutated lung cancer after TKI therapy is due by November 14; it would be the first PD-1xVEGF bispecific cleared in the US. Capricor's DMD cell therapy deramiocel is due November 22 after a 9-3 negative advisory vote.
- Vertex's povetacicept in IgA nephropathy is due by November 30; rivals from Novartis and Vera are already approved. At least 11 action dates fall this month.
Ivonescimab is the cleanest read-through: a progression-free-survival win without a significant overall-survival result at filing, so approval would show how much the FDA discounts a later nominal survival signal. Capricor is the opposite, a negative panel and a prior rejection. Povetacicept is a late entrant, so label and pricing decide how fast it takes share.
Industry NewsVertex PharmaceuticalsBioPharma Dive
Vertex Heads Into a Possible November Povetacicept Approval With a Citizen Petition Over Infection Monitoring
- Vertex says it is ready to launch povetacicept in IgA nephropathy; an FDA approval could come by the end of November.
- A late-October citizen petition asks the FDA to require antibody-level monitoring because of infection risk; Vertex did not directly address it on the call.
- Q3 revenue rose 12% to $3.44 billion, with Alyftrek and Casgevy ahead of estimates and Journavx below; full-year guidance was nudged up to $13.15–13.25 billion.
The petition matters more than the earnings beat: if the label ends up with immunoglobulin monitoring, a monthly home autoinjector loses some of its convenience edge over the two IgAN drugs already on the market. Vertex is also launching a low-volume, highly concentrated device at scale for the first time outside cystic fibrosis, so supply is a second thing to check. The $10 billion Crinetics purchase is weighing on near-term earnings per share.
Industry NewsVertex PharmaceuticalsEndpoints News
Vertex commits over £300M to new Oxford research facility
- Vertex said it will invest more than £300 million in a new R&D facility in Oxford, England.
- The pledge was announced alongside the UK Autumn Budget, as part of a wider set of British biopharma investment commitments.
- Press coverage describes a roughly 155,000 sq ft site at Harwell Campus, with the government contributing an undisclosed grant.
£300M-plus is a serious commitment for a company whose cash engine is still cystic fibrosis, and it reads as a bet on research capacity beyond its US hubs as it pushes into pain, kidney and other new areas. The undisclosed government grant is the tell: the UK is now paying to win R&D sites, not just manufacturing.
Industry NewsVertex PharmaceuticalsFierce Biotech
Vertex's Inaxaplin Hits Phase 2b Marks in Broader APOL1 Kidney Disease Populations
- Vertex's oral APOL1 inhibitor inaxaplin met Phase 2b AMPLIFIED goals in two new AMKD populations beyond the original cohort.
- Among 41 patients, Week 13 UACR fell 42.7% with modest proteinuria (n=23) and 17.3% with AMKD plus type 2 diabetes (n=18).
- This broadens inaxaplin's market as pivotal AMPLITUDE trial enrollment completes, with interim data due early 2027.
APOL1-mediated kidney disease has essentially no targeted competition — a genetically defined, high-unmet-need population overwhelmingly of African ancestry that mainstream nephrology has largely ignored — and Vertex is quietly building the second pillar of its post-CF story there. Widening efficacy into milder-proteinuria and diabetic AMKD subgroups ahead of AMPLITUDE's 2027 readout meaningfully expands the addressable market and de-risks the label.